Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands

• Fay Probert,
• Tianrong Yeo,
• Tianrong Yeo,
• Tianrong Yeo,
• Yifan Zhou,
• Yifan Zhou,
• Yifan Zhou,
• Megan Sealey,
• Siddharth Arora,
• Jacqueline Palace,
• Timothy D. W. Claridge,
• Rainer Hillenbrand,
• Johanna Oechtering,
• Jens Kuhle,
• David Leppert,
• Daniel C. Anthony

Affiliations

Fay Probert

Department of Chemistry, University of Oxford, Oxford, United Kingdom

Tianrong Yeo

Department of Pharmacology, University of Oxford, Oxford, United Kingdom

Tianrong Yeo

Department of Neurology, National Neuroscience Institute, Singapore, Singapore

Tianrong Yeo

Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore

Yifan Zhou

Department of Pharmacology, University of Oxford, Oxford, United Kingdom

Yifan Zhou

Translational Stem Cell Biology Branch, National Institutes of Health, Bethesda, MD, United States

Yifan Zhou

Wellcome Medical Research Council (MRC) Trust Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

Megan Sealey

Department of Pharmacology, University of Oxford, Oxford, United Kingdom

Siddharth Arora

Department of Mathematics, University of Oxford, Oxford, United Kingdom

Jacqueline Palace

Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

Timothy D. W. Claridge

Department of Chemistry, University of Oxford, Oxford, United Kingdom

Rainer Hillenbrand

Biomarker Development, Novartis Pharma AG, Basel, Switzerland

Johanna Oechtering

0Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland

Jens Kuhle

0Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland

David Leppert

0Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland

Daniel C. Anthony

Department of Pharmacology, University of Oxford, Oxford, United Kingdom